136 related articles for article (PubMed ID: 16699254)
1. Long-term bosentan in chronic thromboembolic pulmonary hypertension.
Seyfarth HJ; Hammerschmidt S; Pankau H; Winkler J; Wirtz H
Respiration; 2007; 74(3):287-92. PubMed ID: 16699254
[TBL] [Abstract][Full Text] [Related]
2. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
3. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
[TBL] [Abstract][Full Text] [Related]
4. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
5. Bosentan for patients with chronic thromboembolic pulmonary hypertension.
Vassallo FG; Kodric M; Scarduelli C; Harari S; Potena A; Scarda A; Piattella M; Cassandro R; Confalonieri M
Eur J Intern Med; 2009 Jan; 20(1):24-9. PubMed ID: 19237088
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
Hughes RJ; Jais X; Bonderman D; Suntharalingam J; Humbert M; Lang I; Simonneau G; Pepke-Zaba J
Eur Respir J; 2006 Jul; 28(1):138-43. PubMed ID: 16611652
[TBL] [Abstract][Full Text] [Related]
7. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
Surie S; Reesink HJ; Marcus JT; van der Plas MN; Kloek JJ; Vonk-Noordegraaf A; Bresser P
Clin Cardiol; 2013 Nov; 36(11):698-703. PubMed ID: 24037998
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC
Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.
Baptista R; Castro G; da Silva AM; Monteiro P; Providência LA
Rev Port Cardiol; 2013 Feb; 32(2):123-9. PubMed ID: 23351920
[TBL] [Abstract][Full Text] [Related]
11. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
12. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
[TBL] [Abstract][Full Text] [Related]
15. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D
Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407
[TBL] [Abstract][Full Text] [Related]
18. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Bonderman D; Nowotny R; Skoro-Sajer N; Jakowitsch J; Adlbrecht C; Klepetko W; Lang IM
Chest; 2005 Oct; 128(4):2599-603. PubMed ID: 16236930
[TBL] [Abstract][Full Text] [Related]
19. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
Monfredi O; Griffiths L; Clarke B; Mahadevan VS
Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
